From Materia Medica to Modern Drugs

Identification came first. The same common name could refer to different species, while one plant might have several regional names. Where a substance grew, when it was collected, which part was used, how it was dried, and whether it had been substituted all affected quality. Images helped, but colour, scale, and local variation could make them uncertain guides.

The genre has a long chronology. In Egypt, the Ebers Papyrus (c. 1550 BCE) already compiled hundreds of remedies in a single manuscript. Around 78 CE, Dioscorides of Anazarbus, a physician in the Roman army, wrote De Materia Medica, five books describing roughly 600 plant, animal, and mineral substances with their parts, preparation, and uses. It became the standard pharmacological reference in the Greek, Latin, and Islamic worlds for about fifteen centuries, expanded by Galen (c. 129–c. 216 CE) and later reworked by Islamic physicians such as al-Razi (854–925) and Ibn Sina, whose Canon of Medicine (c. 1025) became a European university textbook.

Preparation was part of the medicine. Grinding, heating, soaking, fermenting, combining, and timing could change potency or toxicity. A recipe might specify a carrier, diet, season, or bodily constitution. Removing an ingredient from that system to search for one chemical effect asks a productive modern question, but it is not the only historical question the source can answer.

Materia medica also accumulated criticism. Compilers compared earlier authorities, practical experience, variant names, and reports from travellers or drug sellers. Textual tradition and observation were not simple opposites; books preserved claims that practitioners tested, amended, and transmitted. During the nineteenth century, national pharmacopoeias, including the United States Pharmacopeia (first published in 1820) and the British Pharmacopoeia (1864), turned selected materia medica entries into official standards of name, strength, and purity.

The groundwork was laid earlier. Paracelsus (1493–1541) argued that medicine should use chemical substances and that the dose, not the category of a substance, decided whether it was a poison or a remedy. His programme did not immediately win, but it made chemical preparation respectable inside medical debate.

Two developments changed practice. In 1785, the English physician William Withering published a careful clinical account of digitalis, the foxglove preparation he used for dropsy, a condition now understood as fluid retention often associated with heart failure. In 1804, the German pharmacist Friedrich Sertürner isolated morphine from opium, the first time an active principle was separated from a plant that had been used medicinally for millennia. Isolation made dose control possible and created the model for later "active principle" research.

Quinine shows how trade and chemistry intertwined. Cinchona bark, known for its antimalarial use in the Andes, reached Europe through Jesuit missionaries in the seventeenth century and became a major colonial commodity; the story that it first cured the Countess of Chinchón is a later legend rather than a documented case. The Spanish crown tried to control the supply, and nineteenth-century Dutch colonial plantations in Java eventually dominated production. In 1820, the French chemists Pierre-Joseph Pelletier and Joseph-Bienaimé Caventou isolated quinine from the bark, turning a variable imported drug into a measurable substance.

By the end of the century, industry had entered the chain. In 1899, the German firm Bayer began marketing acetylsalicylic acid under the brand name Aspirin, one of the first modern brand-name drugs, produced to a defined chemical standard and sold through advertising as much as through prescription.

1. c. 1550 BCE: The Ebers Papyrus compiles Egyptian remedies in a single manuscript.
2. c. 78 CE: Dioscorides writes De Materia Medica, the standard pharmacological text for the next fifteen centuries.
3. 1552: The Badianus Codex records Nahua medicinal plants in Latin at the Colegio de Santa Cruz de Tlatelolco.
4. 1578: Li Shizhen completes the Bencao Gangmu, 1,892 entries in fifty-two juan.
5. 1785: William Withering publishes his clinical account of digitalis.
6. 1804: Friedrich Sertürner isolates morphine from opium.
7. 1820–1864: Quinine is isolated from cinchona bark and national drug standards expand: the United States Pharmacopeia appears in 1820 and the British Pharmacopoeia in 1864.
8. 1899: Bayer markets acetylsalicylic acid as Aspirin.
9. 1906–1962: United States drug law moves from policing adulteration (1906) to requiring safety (1938) and efficacy (1962).
10. 1967–1972: Project 523 isolates artemisinin from sweet wormwood.

Botanical identification and chemical extraction could narrow a variable preparation into an active fraction or compound. Researchers then investigated dose, toxicity, absorption, and mechanism. This work made repeatable comparison possible, but it might leave behind other ingredients, preparation methods, or therapeutic rationales contained in the original practice.

Tu Youyou's artemisinin work shows a more complex route. Project 523, launched in 1967 to find new antimalarials as chloroquine resistance spread, surveyed thousands of traditional recipes while using modern extraction and experimental testing. A passage attributed to Ge Hong in the fourth-century Zhouhou Beiji Fang (A Handbook of Prescriptions for Emergencies) described soaking sweet wormwood in water and wringing out the juice rather than boiling it. That older instruction about preparation redirected the team toward a low-temperature ether extract, obtained in 1971, which showed complete antimalarial activity in animal tests; human trials followed in 1972 in Hainan and at Beijing's No. 302 Hospital. The result was neither the simple validation of an unchanged ancient remedy nor a discovery detached from textual knowledge. Tu Youyou received the 2015 Nobel Prize in Physiology or Medicine for the discovery.

Standardisation extends beyond the laboratory. Cultivation, harvesting, storage, purity, manufacturing, packaging, and shelf life must be controlled. A stable dose depends on farmers, supply chains, engineers, analytical methods, factories, regulators, and inspection. The history of a modern drug is therefore also a history of infrastructure.

Standardisation was not only a laboratory problem; it required public authority. In the United States, the Pure Food and Drugs Act of 1906 prohibited interstate commerce in adulterated and misbranded drugs, a law driven in part by the work of Harvey Washington Wiley in the Department of Agriculture. The act policed what was in a product and what its label claimed, but it did not require proof that a drug was safe.

That changed after 1937, when an untested liquid sulfonamide, made with the toxic solvent diethylene glycol, killed more than 100 people, many of them children. The Federal Food, Drug, and Cosmetic Act of 1938 then required manufacturers to show that a new drug was safe before it could be marketed. The next step came after thalidomide, a sedative and anti-nausea drug sold in many countries from the late 1950s that caused severe birth defects. The Kefauver-Harris Amendments of 1962 required manufacturers to demonstrate efficacy as well as safety and tightened the rules for clinical testing.

These United States milestones were not universal, but they marked a turning point: a drug's identity now depended on regulated evidence, not only on chemical definition. Regulation also created new dependencies, because approval required documentation, inspection, and ongoing surveillance that small producers and traditional markets could not easily meet.

Colonial botanical networks often moved plants and information without recognising the people who cultivated, identified, or used them. Cinchona bark illustrates the chain: its antimalarial use was known in the Andes, Jesuit missionaries carried it to Europe in the 1630s, the Spanish crown tried to keep the supply monopoly, and the Dutch colonial government and later private estates cultivated the tree in Java, eventually dominating production. The knowledge travelled through empire long before its active principle was isolated in 1820. Scientific names and patents could then make that knowledge appear newly owned after it entered a laboratory. Modern debates over bioprospecting, prior knowledge, consent, and benefit-sharing grow from this longer history.

Recognition alone does not guarantee justice. A community may be credited while remaining unable to afford the therapy, control the resource, or influence how its knowledge is represented. International law has tried to address the history: the Convention on Biological Diversity (1992) and the Nagoya Protocol (2010) frame access to genetic resources and associated traditional knowledge in terms of consent and benefit-sharing, although enforcement remains uneven. Conservation matters too: demand for a medicinal species can damage habitats or livelihoods unless cultivation and trade are managed sustainably.

The most responsible histories therefore connect efficacy with political economy. They ask not only whether a remedy “worked,” but who supplied it, who transformed it, who assumed risk, who claimed intellectual property, and who gained access to the finished medicine.

Materia medica and pharmaceuticals should not be arranged as superstition followed by science. Historical practitioners investigated substances within different explanatory and evidentiary systems; modern pharmacology developed powerful ways to isolate, measure, and test them. The relationship is one of translation and transformation.

Seeing that chain prevents two opposite errors: romanticising everything traditional as proven, and presenting modern drugs as inventions without social or environmental ancestry. Medicines become intelligible when textual knowledge, practical expertise, experiment, production, safety, ownership, and access remain in the same history.